<DOC>
	<DOCNO>NCT01374503</DOCNO>
	<brief_summary>The purpose first-in-man Phase I study determine whether CXCR4-inhibitor ALX-0651 safe effective single multiple intravenous administration healthy male volunteer .</brief_summary>
	<brief_title>First Man Study ALX-0651 , Nanobody Inhibiting CXCR4</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer , age &gt; = 18 &lt; = 55 screening . Willing consent use effective contraceptive method least 3 month test substance administration . Nonsmokers , exsmokers abstinent tobacco least 1 year . Body mass index ( BMI ) : 19 29 kg/m2 ( extremes include ) . Haematology chemistry parameter within normal range show clinically relevant deviation , judge Medical Investigator . For haematology , haemoglobin white blood cell ( WBC ) count must within normal limit . For chemistry , calcium , alkaline phosphatase ( ALP ) , ( alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyl transferase ( GGT ) lactate dehydrogenase ( LDH ) must within normal limit . Normal electrocardiogram , show clinically relevant deviation , judge Investigator . QTc &lt; = 450 ms. No history presence diseases kidney , heart , lung , liver , gastrointestinal tract endocrine organ , condition know interfere absorption , distribution , metabolism excretion drug . No history clinically relevant allergy . Obtained , sign date informed consent . Ability willingness comply protocol requirement . Intake prescribed systemic topical medication within 14 day prior dose . Intake vitamin A derivates retinoids within 30 day prior start drug administration . History thrombosis . Chronic infection acute significant infection fever within last 5 week prior start test substance administration . Subjects abnormality spleen ( confirm echography ) history splenic disease , subject underwent splenectomy past . Blood donation ( &gt; 500 ml ) comparable blood loss within three month prior start drug administration . Subjects , investigator 's opinion , may capable follow study schedule reason , special emphasis eligibility aphaeresis procedure . Participation investigational drug study within 60 day prior drug administration , within less 6 time terminal elimination halflife test substance use respective trial ( whichever longer ) . Malignancy , prior malignancy , diseasefree interval &lt; 5 year diagnosis intervention , except curative treatment nonmelanoma skin cancer resect carcinoma situ .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>